Supernus Pharmaceuticals SUPN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's operating income?
- Supernus Pharmaceuticals (SUPN) reported operating income of -$8.33M in Q1 2026.
- How has Supernus Pharmaceuticals's operating income changed year-over-year?
- Supernus Pharmaceuticals's operating income increased by 18.8% year-over-year, from -$10.26M to -$8.33M.
- What is the long-term trend for Supernus Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's operating income has grown at a -7.8% compound annual growth rate (CAGR), from $86.03M to -$62.28M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.